Literature DB >> 15857134

Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.

Hirokazu Tamamura1, Takanobu Araki, Satoshi Ueda, Zixuan Wang, Shinya Oishi, Ai Esaka, John O Trent, Hideki Nakashima, Naoki Yamamoto, Stephen C Peiper, Akira Otaka, Nobutaka Fujii.   

Abstract

A highly potent CXCR4 antagonist, compound 2, was previously found by using two orthogonal cyclic pentapeptide libraries involving conformation-based and sequence-based libraries based on the pharmacophore of a 14-mer peptidic antagonist, 1. Herein, cyclic tetrapeptides derived from replacements of the dipeptide unit (Nal-Gly) with a gamma-amino acid and pseudopeptides cyclized by disulfide and olefin bridges were synthesized to find novel scaffold structures different from that of cyclic pentapeptides. These compounds contain a reduced number of peptide bonds compared to compound 2. Furthermore, several analogues with chemical modification of the side chain of Arg(4) in 2 were also prepared. From these, several new leads possessing high to moderate CXCR4-antagonistic activity were characterized.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857134     DOI: 10.1021/jm050009h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

2.  Rational design of alpha-conotoxin analogues targeting alpha7 nicotinic acetylcholine receptors: improved antagonistic activity by incorporation of proline derivatives.

Authors:  Christopher Armishaw; Anders A Jensen; Thomas Balle; Richard J Clark; Kasper Harpsøe; Christian Skonberg; Tommy Liljefors; Kristian Strømgaard
Journal:  J Biol Chem       Date:  2009-01-08       Impact factor: 5.157

3.  Potent CXCR4 antagonists containing amidine type Peptide bond isosteres.

Authors:  Eriko Inokuchi; Shinya Oishi; Tatsuhiko Kubo; Hiroaki Ohno; Kazuya Shimura; Masao Matsuoka; Nobutaka Fujii
Journal:  ACS Med Chem Lett       Date:  2011-03-28       Impact factor: 4.345

Review 4.  Peptide and protein-based inhibitors of HIV-1 co-receptors.

Authors:  Horst A von Recum; Jonathan K Pokorski
Journal:  Exp Biol Med (Maywood)       Date:  2013-05

5.  Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.

Authors:  Ana Montero; John M Beierle; Christian A Olsen; M Reza Ghadiri
Journal:  J Am Chem Soc       Date:  2009-03-04       Impact factor: 15.419

Review 6.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

7.  Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.

Authors:  S Thiele; J Mungalpara; A Steen; M M Rosenkilde; J Våbenø
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

8.  Conformationally homogeneous heterocyclic pseudotetrapeptides as three-dimensional scaffolds for rational drug design: receptor-selective somatostatin analogues.

Authors:  John M Beierle; W Seth Horne; Jan H van Maarseveen; Beatrice Waser; Jean Claude Reubi; M Reza Ghadiri
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

9.  PET imaging of CXCR4 receptors in cancer by a new optimized ligand.

Authors:  Oliver Demmer; Eleni Gourni; Udo Schumacher; Horst Kessler; Hans-Jürgen Wester
Journal:  ChemMedChem       Date:  2011-07-20       Impact factor: 3.466

Review 10.  Small molecule inhibitors of CXCR4.

Authors:  Bikash Debnath; Shili Xu; Fedora Grande; Antonio Garofalo; Nouri Neamati
Journal:  Theranostics       Date:  2013-01-15       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.